Can Alpha Tau Medical Answer What Happens When Trial Data Arrives Before Revenue Does?

Alpha Tau Medical Ltd. (DRTS) is scheduled to report Q1 2026 earnings before the market opens on Monday, May 18, with a conference call set for Tuesday, May 19 at 4:00 PM ET. The company faces a critical test as it seeks to demonstrate progress following its landmark Japanese regulatory approval while managing investor expectations around its expanding clinical trial portfolio. With the stock trading at $10.36 and showing strong momentum into the release, the question is whether Alpha Tau can deliver results that justify the recent rally and support its ambitious global expansion plans.

Part 1: Earnings Preview

Alpha Tau Medical is a clinical-stage biotechnology company developing Alpha DaRT, an innovative alpha-radiation cancer therapy platform designed to treat solid tumors. The company's technology has received marketing approval in Israel and, as of February 2026, in Japan for unresectable locally advanced or locally recurrent head and neck cancer—marking its first regulatory approval outside Israel.

For Q1 2026, analysts expect Alpha Tau to report a loss of $0.13 per share on revenue of $0.047 million. The company most recently reported Q4 2025 earnings of -$0.14 per share, missing the consensus estimate of -$0.13 by $0.01. Compared to the same quarter last year (Q1 2025), when the company reported -$0.12 per share, the current estimate represents an 8.33% increase in losses year-over-year.

Three key themes define this earnings story:

Japanese Market Entry and Post-Market Surveillance: Following the February 2026 regulatory approval in Japan, investors will be watching for updates on the post-market surveillance study requiring 66 patients across five clinical centers. This represents Alpha Tau's first major commercial opportunity outside Israel and could validate the platform's global potential.

Clinical Trial Momentum: With five clinical trials now approved in parallel in the U.S., including studies in pancreatic cancer and other high-unmet-need indications, the pace of clinical development has accelerated dramatically. Recent data presented at the 2026 ASCO Symposium showed a 23% overall response rate in pancreatic cancer (excluding initial low-dose feasibility patients), and investors will be looking for enrollment updates and timeline guidance.

Manufacturing Scale-Up and Pre-Commercial Preparations: As CEO Uzi Sofer noted in March, the company is building out manufacturing capabilities in New Hampshire while entertaining "multiple tracks of strategic dialogue with partners." Any commentary on manufacturing readiness, capacity expansion, or partnership discussions could significantly impact investor sentiment.

Analyst commentary ahead of the release reflects cautious optimism. HC Wainwright maintains a buy rating with a $12.00 target, citing the expanding clinical pipeline and regulatory progress. However, Piper Sandler holds a neutral stance with a $5.00 target, suggesting concerns about the path to profitability. Citigroup recently raised its target from $7.00 to $9.00 following the Japanese approval, indicating growing confidence in the commercial trajectory.

Part 2: Historical Earnings Performance

Alpha Tau has demonstrated an inconsistent earnings track record over the past four quarters, with a pattern of both beats and misses against analyst expectations. In Q1 2025, the company beat estimates by 14.29%, reporting -$0.12 versus the expected -$0.14. However, this was followed by three consecutive misses: Q2 2025 missed by 8.33% (-$0.13 vs. -$0.12 expected), Q3 2025 missed by 16.67% (-$0.14 vs. -$0.12 expected), and most recently Q4 2025 missed by 7.69% (-$0.14 vs. -$0.13 expected).

The trend reveals deteriorating performance relative to expectations, with losses consistently coming in worse than analysts anticipated over the past three quarters. The company's actual losses have ranged from -$0.12 to -$0.14 per share, showing relatively stable absolute performance but a pattern of falling short of increasingly optimistic analyst forecasts. This suggests analysts may have been too aggressive in modeling expense management or revenue ramp, particularly as the company invests heavily in clinical trials and manufacturing infrastructure.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Alpha Tau typically reports earnings before the market opens, meaning Day 0 represents the first full trading session where investors react to results, while Day +1 captures follow-through momentum.

Historical price behavior around earnings shows significant volatility, with an average absolute Day 0 move of 4.19% and Day +1 move of 4.28%. The stock has exhibited particularly dramatic reactions in recent quarters: the May 2025 report triggered an 11.11% Day 0 surge, while the November 2025 release saw a 5.71% Day 0 decline followed by a 10.09% Day +1 rally. The average Day 0 trading range of 6.80% and Day +1 range of 8.35% indicate substantial intraday volatility regardless of direction. Investors should prepare for meaningful price swings, with recent history suggesting the potential for double-digit percentage moves in either direction depending on whether the company beats or misses estimates and provides compelling forward guidance.

Part 2.2: Options Market Expected Move

The options market is pricing in an expected move of 20.18% ($2.09) through the June 18 expiration, significantly higher than the stock's average historical Day 0 move of 4.19% and Day +1 move of 4.28%. This elevated implied volatility of 94.59% suggests options traders are anticipating an outsized reaction to this earnings release, possibly reflecting heightened uncertainty around the Japanese market opportunity, clinical trial updates, or potential partnership announcements.

Part 3: What Analysts Are Saying

Analyst sentiment on Alpha Tau is mixed, with a consensus rating of 4.00 (Buy) and an average price target of $11.33—implying approximately 9.4% upside from the current price of $10.36. The analyst community is evenly split, with 2 Strong Buy ratings and 2 Hold ratings, and no sell recommendations. Price targets range widely from a low of $5.00 (Piper Sandler) to a high of $15.00, reflecting divergent views on the company's commercial prospects.

The sentiment trend is unchanged from one month ago, with the same 4.00 rating and identical distribution of recommendations. This stability suggests analysts are taking a wait-and-see approach ahead of the Q1 report, likely wanting to assess progress on the Japanese post-market surveillance study and U.S. clinical trial enrollment before making significant rating changes. The wide target range—spanning $10.00 from low to high—underscores the binary nature of the investment thesis, where bulls see transformative potential in the Alpha DaRT platform while skeptics question the timeline to meaningful revenue generation and profitability.

Part 4: Technical Picture

Alpha Tau enters earnings with exceptionally strong technical momentum. The Barchart Technical Opinion currently stands at 100% Buy, maintaining maximum bullish strength from both one week ago (100% Buy) and one month ago (88% Buy). This represents a notable strengthening of the signal over the past month, reflecting the stock's powerful rally from lower levels.

Timeframe Analysis:

• Short-term (100% Buy): Maximum buy signal indicates powerful near-term momentum heading into the earnings release
• Medium-term (100% Buy): Strong bullish reading confirms the uptrend is well-established across intermediate timeframes
• Long-term (100% Buy): Maximum long-term buy signal suggests the stock has broken out to new structural highs

Trend Characteristics: The combination of Maximum strength and Strongest direction indicates Alpha Tau is in an exceptionally powerful uptrend across all timeframes, providing a supportive technical backdrop for the earnings release.

The stock is trading above all key moving averages, confirming broad-based bullish momentum: $10.36 versus the 5-day MA of $10.13, 20-day MA of $8.46, 50-day MA of $7.69, 100-day MA of $7.24, and 200-day MA of $5.56. This alignment—with the stock trading 86% above its 200-day average—reflects a sustained breakout that began earlier this year. The 52-week range of $2.78 to $10.80 shows the stock is trading near its annual high, with the current price just $0.44 (4%) below the peak. The technical setup is highly supportive heading into earnings, though the extended nature of the rally means the stock could be vulnerable to profit-taking if results disappoint or fail to provide catalysts justifying current valuations.